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ABSTRACT
Thyroid hormone regulates terminal differentiation of growth plate chondrocytes in part through modulation of the Wnt/b-catenin
signaling pathway. Insulin-like growth factor 1 (IGF-1) has been described as a stabilizer of b-catenin, and thyroid hormone is a known
stimulator of IGF-1 receptor expression. The purpose of this study was to test the hypothesis that IGF-1 signaling is involved in the
interaction between the thyroid hormone and the Wnt/b-catenin signaling pathways in regulating growth plate chondrocyte
proliferation and differentiation. The results show that IGF-1 and the IGF- receptor (IGF1R) stimulate Wnt-4 expression and b-catenin
activation ingrowth platechondrocytes.Thepositiveeffects ofIGF-1/IGF1Ronchondrocyteproliferation andterminaldifferentiationare
partially inhibited by the Wnt antagonists sFRP3 and Dkk1. T3 activates IGF-1/IGF1R signaling and IGF-1-dependent PI3K/Akt/GSK-3b
signaling in growth plate chondrocytes undergoing proliferation and differentiation to prehypertrophy. T3-mediated Wnt-4 expression,
b-catenin activation, cell proliferation, and terminal differentiation of growth plate chondrocytes are partially prevented by the IGF1R
inhibitor picropodophyllin as well as by the PI3K/Akt signaling inhibitors LY294002 and Akti1/2. These data indicate that the interactions
between thyroid hormone and b-catenin signaling in regulating growth plate chondrocyte proliferation and terminal differentiation are
modulated by IGF-1/IGF1R signaling through both the Wnt and PI3K/Akt signaling pathways. While chondrocyte proliferation may be
triggered by the IGF-1/IGF1R-mediated PI3K/Akt/GSK3b pathway, cell hypertrophy is likely due to activation of Wnt/b-catenin signaling,
which is at least in part initiated by IGF-1 signaling or the IGF-1-activated PI3K/Akt signaling pathway.  2010 American Society for Bone
and Mineral Research.
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Introduction
D
uring longitudinal bone growth, growth plate chondrocyte
proliferationanddifferentiationareregulatedbyavarietyof
endocrine and paracrine hormones and growth factors. Local
paracrine regulators that areessential fornormal boneformation
include bone morphogenetic proteins (BMPs), Wnts, parathyroid
hormone-related protein (PTHrP), Indian hedgehog (Ihh), and
insulin-like growth factor 1 (IGF-1).
(1) PTHrP and Ihh interact in a
negative-feedback loop to regulate the transition from pro-
liferation to differentiation in growth plate chondrocytes. Wnt
and BMP signaling are cooperative signaling pathways that
promote chondrocyte terminal differentiation. Several investi-
gators, including our laboratory, have identified Wnt-4 as a
positive regulator of terminal differentiation of growth plate
chondrocytes.
(2–4)
IGF-1 has been shown to be an important regulator of
endochondral ossification.
(5–11) IGF-1 stimulates proliferation of
resting-zone chondrocytes, augments chondrocyte hypertrophy,
and promotes longitudinal bone growth.
(5–7) The effects elicited
by the systemic administration of IGF-1 to hypophysectomized
rats suggest that IGF-1 stimulates growth plate chondrocytes at
all stages of differentiation.
(5) Local infusion of IGF-1 in the rabbit
tibial growth plate results in an acceleration of the tibial growth
rate and an increased number of proliferative and hypertrophic
growth plate chondrocytes.
(6) In fetal mouse metatarsals, IGF-1
induces cell proliferation and hypertrophy in the growth plate.
(7)
IGF-1 signaling is also required to maintain the Ihh-PTHrP loop
duringskeletogenesis.InfetalIgf1
 / mice,expressionofIhhwas
reduced in long bones, whereas expression of PTHrP was
increased.
(8) Igf1 null mice exhibit severe prenatal growth plate
defects and a subnormal postnatal growth rate.
(9,10) The tibial
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1138growth plate in the Igf1 null mice exhibits an expanded resting
zone and a significantly reduced hypertrophic zone.
(11)
IGF-1 signals via the type 1 IGF receptor (IGF1R), which is
expressed in the proliferating and prehypertrophic zone
chondrocytes of growth plate,
(12) which is similar in localization
to PTHrP and PTH/PTHrP receptor expression.
(8) Compared with
Igf1
 /  mice, null mutants for the Igf1r gene exhibit even more
severe growth retardation.
(9) The growth plates of Igf1r
 / 
mouse embryos show delayed chondrocyte maturation and
poor formation of primary ossification centers.
(10) The action of
IGF-1 within the growth plate is also regulated by IGF-binding
proteins (IGFBPs), which bind IGF with high affinity and
potentially can either inhibit or enhance IGF activity depending
on the complement of IGFBPs present.
(13)
Thyroid hormone is a systemic factor that potently regulates
skeletal maturation in the growth plate. Thyroid hormone
receptor a (TR-a) is essential for regulating the process of
endochondrial ossification. TRa1
PV/þ mice, which are lacking TRa1,
exhibit skeletal hypothyroidism with delayed endochondral
ossification and severe postnatal growth retardation.
(14)TRa1
PV/þ
mice also have impaired Igf1r expression and IGF-1 signaling in the
growth plate, suggesting that the IGF1R is a physiologic target for
thyroid hormone action in the growth plate.
(14)
b-Catenin signaling also has been recognized as an important
signal-transduction pathway in regulating terminal differentia-
tion of growth plate chondrocytes. Inhibition of b-catenin
signaling in Col2a1-ICAT transgenic mice results in reduced
chondrocyte proliferation and differentiation, delayed formation
of the secondary ossification center, and reduced skeletal
growth.
(15) Our previous studies have shown that thyroid
hormone interacts with the Wnt/b-catenin signaling pathway
in regulating the terminal differentiation of growth plate
chondrocytes.
(4)
GSK-3b is a negative regulator of the canonical Wnt/b-catenin
pathway.
(16) b-Catenin is phosphorylated by active GSK-3b and
targeted for degradation. Wnt ligands inhibit the formation of
the axin/APC/GSK3 complex and block b-catenin phosphoryla-
tion by GSK-3b, resulting in the stabilization of b-catenin.
GSK-3b is also involved in the IGF-1 signaling pathway.
Phosphatidylinositol-3-kinase (PI3K) is an important signal
transducer of responses to IGF-1 signaling. Akt is a downstream
target of PI3K, and can inactivate GSK-3b by phosphorylation on
serine 9.
(17)Igf1
 /  mice exhibit hypophosphorylated GSK-3b in
the tibial growth plates.
(11) Raucci and colleagues reported that
IGF-1 signals induce Akt phosphorylation and promote osteo-
blast differentiation, and cells expressing active Akt have
increased levels of stabilized b-catenin.
(18) IGF-1 also regulates
the location, stability, and transcriptional activity of b-catenin in
cancer cells.
(19)
These observations support the concept of crosstalk between
IGF-1 and Wnt signaling pathways in regulating growth plate
chondrocyte differentiation. IGF-1 signals may potentiate the
biologic functions of Wnt signaling by modulating b-catenin
signaling through PI3K/Akt pathway. The purpose of this study
was to test the hypothesis that thyroid hormone regulates
proliferation and differentiation of growth plate chondrocytes
throughIGF-1modulationoftheactivityofb-cateninsignalingin
growth plate chondrocytes.
Materials and Methods
Cell culture
Chondrocytes were isolated from the resting zone of the distal
femoral growth plate of 2-day-old neonatal Sprague-Dawley rats
bysequentialdigestionintrypsin/EDTA(Invitrogen,Carlsbad,CA,
USA) for 1 hour at 378C, followed by 0.3% collagenase type I
(Worthington, Lakewood, NJ, USA) for 4 hours at 378C.
(20) Cells
were resuspended in DMEM/F12 medium (Invitrogen) supple-
mented with a defined medium supplement (ITSþ1, Sigma, St.
Louis, MO, USA) and plated in monolayer or in 3D pellet
cultures.
(4) Triiodothyronine (T3, Sigma) was added to the
medium at a concentration of 100ng/mL. Recombinant mouse
IGF-1, Frzb/sFRP3, and Dkk1 (R&D Systems, Minneapolis, MN,
USA) were used at concentrations of 50, 100, and 100ng/mL,
respectively.TheIGF1Rinhibitorpicropodophyllin (PPP),thePI3K
inhibitorLY294002,andthe AktinhibitorAkti1/2werepurchased
from Calbiochem (La Jolla, CA, USA) and used at concentrations
of 1, 20, and 1mM, respectively.
An adenovirus encoding the IGF1R (Ad-IGF1R) was kindly
supplied by Dr Delafontaine (Tulane University School of
Medicine, New Orleans, LA, USA). The adenovirus was used at
a multiplicity of infection (MOI) of 50. A structurally similar
adenoviruscontainingthe Cytomegalovirus(CMV)promoter was
used as a negative control. Growth plate chondrocytes were
infected with adenoviral vectors in 60-mm dishes. Twenty-four
hours after infection, the cells in monolayer were trypsinized and
maintained as pellet cultures.
Quantitative real-time PCR
Total RNA was isolated from cultured growth plate chondrocytes
usingthe RNeasy Kit(Qiagen, Valencia,CA, USA)according tothe
manufacturer’s instructions. Reverse transcription was per-
formed using random primers and Superscript III DNA
polymerase (Invitrogen). Real-time polymerase chain reaction
(PCR) reactions were conducted in an ABI Prism 7700 Sequence
Detection System using SYBR Green PCR core reagents (Applied
Biosystems, Foster City, CA, USA). The forward and reverse
primers for the amplifications were as follows: IGF-1: 5’-GC-
TATGGCTCCAGCATTCG-3’ and 5’-AGATCACAGCTCCGGAAGCA-
3’; IGF1R: 5’-CCTGGCGTGCTGGTTCTC-3’ and 5’-GGCGCGTCCCCC-
ATT-3’; Wnt-4: 5’-AACCGGCGCTGGAACTG-3’ and 5’-GGTCCCTTG-
TGTCACCACCTT-3’; cyclin D1: 5’-CCCACGATTTCATCGAACACT-3’
and 5’-GTGCATGTTTGCGGATGATC-3’; Runx2/cbfa1: 5’-TTTAGGG-
CGCATTCCTCATC-3’ and 5’-GGAGGGCCGTGGGTTCT-3’; Col10a1:
5’-GATCATGGAGCTCACGGAAAA-3’ and 5’-CCGTTCGATTCCGC-
ATTG-3’; and 18s: 5’-AGTCCCTGCCCTTTGTACACA-3’ and 5’-GA-
TCCGAGGGCCTCACTAAAC-3’.
Cell proliferation assay
Cells from the resting-zone growth plate were plated at a density
of 2.5 10
3 cells per well on 96-well plates. Cells were incubated
in medium supplemented with or without T3, PPP, IGF-1, and Ad-
IGF1R for 5 days. Proliferation was assessed by measuring the
incorporation of 5-bromo-2’-deoxyuridine (BrdU) into DNA using
the BrdU Cell Proliferation Assay Kit (Exalpha Biologicals, Shirley,
MA, USA) according to the manufacturer’s instructions. The
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microplate spectrophotometer at a wavelength of 450nm with
reference at a wavelength of 570nm.
Immunoblotting
Whole-cell extracts were prepared from cultured chondrocytes
using modified RIPA buffer (50mM Tris-HCl, pH 7.4; 1% NP-40;
0.25% sodium deoxycholate; 150mM NaCl; 1mM EDTA; 1mM
PMSF; 1mg/mL each of aprotinin, leupeptin, and pepstatin;
1mMNa 3VO4; and 1mM NaF). An equal amount of protein was
separated by 10% SDS-PAGE and transferred onto nitrocellulose
membranes. The cellular accumulation of active b-catenin was
detected using an antibody against b-catenin (Sigma). Antibody
against IGF1R was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Antibodies against phosphorylated Akt
(pAkt) and phosphorylated GSK-3b (pGSK-3b) were obtained
from Cell Signaling Technology (Beverly, MA, USA). Anti-b-actin
(Sigma) was used as an internal control. The blots were
incubated with a horseradish peroxidase (HRP)–conjugated
secondary antibody (Santa Cruz). Immunoreactive proteins were
visualized by Western blotting chemiluminescence luminol
reagent (Santa Cruz).
Enzyme-linked immunosorbent assay (ELISA)
Secretion of IGF-1 from the pelletcultured growth plate cells into
the culture medium was measured 1 to 8 days after addition of
100ng/mL of T3 using a mouse/rat IGF-1 ELISA quantikine kit
(R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s instructions. The level of IGF-1 in the medium
was normalized to the total protein content of each pellet.
Alkaline phosphatase activity assay
Alkaline phosphatase activity was measured in growth plate
chondrocytes in pellet cultures. Pellets were homogenized, and
Fig. 1. Thyroid hormone treatment increases Igf1r expression in rat growth plate chondrocytes. (A, C) Quantitative real-time RT-PCR analysis of Igf1r and
Igf1 mRNA expression in pellet cultures of growth plate chondrocytes treated with 100ng/mL of T3 for 1 to 8 days. The expression in T3-treated cells was
normalized to the expression in control cells. (B) Immunoblotting of IGF1R protein from whole-cell lysates of growth plate chondrocytes treated with or
withoutT3(100ng/mL)for2to7days.Actinwasusedasaninternalcontrol.(D)DetectionofIGF-1proteininculturemediumofgrowthplatechondrocytes
treatedwithorwithoutT3for1to8days.(E,F)CyclinD1mRNAandBrdUincorporationingrowthplatecellstreatedwithorwithoutT3for1to8days.(G,H)
Col10a1 mRNA and alkaline phosphatase activity in growth plate chondrocytes treated with or without T3 for 1 to 8 days.
 p<.05 versus control cells.
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previously using p-nitrophenyl phosphate (Sigma) as a sub-
strate.
(20) One unit of alkaline phosphatase was defined as
the enzyme activity that liberated 1mmol of p-nitrophenol per
30 minutes at 378C per milligram of protein.
Statistical analysis
All data were represented as mean SD. Values were assessed
by one-way ANOVA with the Bonferroni post hoc test or
Student’s t test at a significance level of p<.05.
Results
T3 upregulates Igf1r expression in proliferating and
prehypertrophic growth plate cells
Igf1r mRNA expression was increased in pellet cultures of growth
platecellstreatedwithT3asearlyasday2,withthepeakincrease
in expression at day 5 of T3 treatment and decreased expression
thereafter (Fig. 1A). To confirm that the increase in gene
expression indeed resulted in a corresponding increase in IGF1R
protein, immunoblotting was performed and demonstrated an
increase in IGF1R on day 4 of T3 treatment, with the level
decreasing on day 7 (Fig. 1B).
Expression of Igf1 mRNA in growth plate cells was transiently
upregulated by T3treatment on day 1and started todecrease on
day 5 of T3 treatment (Fig. 1C). IGF-1 protein secreted into the
medium from the cultured growth plate cells was increased
within the first 2 days of T3 treatment (Fig. 1D).
Chondrocytes collected from the resting-zone growth plate
did not hypertrophy in pellet cultures for at least 2 weeks when
treated with basic medium without T3 (data not shown). To
understand the cell differentiation stage of the growth plate
chondrocytes treated with T3, the cell proliferation markers
cyclin D1 mRNA and BrdU incorporation, as well as cell
hypertrophic markers Col10a1 mRNA and alkaline phosphatase
(ALP) activity, were analyzed in the pellet cultures of growth
plate cells treated with or without T3 for 1 to 8 days. The results
showed that cyclin D1 mRNA expression and BrdU incorporation
peaked on day 5 of T3 treatment (Fig. 1E, F), and Col10a1 mRNA
expression and ALP activity started increasing on day 5 and
reached the highest levels after 8 days of treatment (Fig. 1G, H).
Fig. 2. The inhibitor ofIGF1R decreasesT3-inducedWnt/b-cateninactivation,cell proliferation,and terminaldifferentiation in growthplate chondrocytes.
(A) Quantitative RT-PCR analysis of Wnt4 mRNA expression in growth plate chondrocytes treated with T3 (100ng/mL) and/or the IGF1R inhibitor
picropodophyllin (PPP, 1mM) for 5 days. The expression in T3-treated cells was normalized to the expression in control cells. (B) Immunoblotting of active
b-catenin protein from whole-cell lysates of growth plate chondrocytes treated with T3 and/or PPP for 7 days. Actin was used as an internal control. (C)
Detection of BrdU incorporation of growth plate chondrocytes treated with T3and/or PPP for 5 days. (D) Cyclin D1 mRNA expression in growth plate
chondrocytes treated with T3and/or PPP for 5 days. (E, F) Col10a1 mRNA and alkaline phosphatase activity in growth plate chondrocytes treated
with T3and/or PPP for 5 days.
 p<.05 versus the cells treated with T3 alone.
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proliferating or prehypertrophic stage after 5 days of T3
treatment, whereas most cells hypertrophied when treated
with T3 for 8 days. Upregulation of Igf1r expression by T3
appeared to occur in growth plate chondrocytes undergoing
both proliferation and prehypertrophy.
IGF1R inhibitor attenuates T3-mediated Wnt/b-catenin
signaling, cell proliferation, and terminal differentiation
Picropodophyllin (PPP) is an inhibitor of the IGF1R tyrosine
phosphorylation.
(21) PPP inhibited T3-induced increases of
Wnt4 mRNA expression (Fig. 2A) and cellular accumulation of
active b-catenin (Fig. 2B). PPP decreased T3-mediated cell
proliferation, as assessed by BrdU incorporation (Fig. 2C) and
cyclin D1 mRNA expression (Fig. 2D). PPP also inhibited the
T3-mediated hypertrophy of growth plate chondrocytes, as
assessed by Col10a1 mRNA expression (Fig. 2E) and ALP activity
(Fig. 2F).
IGF-1/IGF1R promotes Wnt/b-catenin signaling activation,
cell proliferation, and terminal differentiation
Incubation of the Ad-IGF1R-infected growth plate cells with
50ng/mL of recombinant IGF-1 protein for 5 days upregulated
the expression of Wnt4 mRNA (Fig. 3A), increased cellular
accumulation of b-catenin (Fig. 3B), and stimulated the
expression of the Wnt/b-catenin response genes Runx2/cbfa1
(Fig. 3C) and cyclin D1 (Fig. 3D) in the growth plate chondrocytes.
IGF-1 and Ad-IGF1R also increased BrdU incorporation by 5 days
oftreatment(Fig.3E)andincreasedCol10a1mRNAexpressionby
8 days of treatment (Fig. 3F).
Wnt antagonists attenuate the effects of IGF-1/IGF1R on
b-catenin signaling, cell proliferation, and terminal
differentiation
The stimulatory effects of IGF-1/IGF1R on growth plate
chondrocytes were partially reversed by the Wnt antagonists
Frzb/sFRP3andDkk1atconcentrationsof100ng/mL.BothsFPR3
Fig. 3. IGF-1/IGF1R promotes Wnt/b-catenin signaling, cell proliferation, and terminal differentiation of growth plate chondrocytes. (A) Quantitative RT-
PCR analysis of Wnt4 mRNA expression in rat growth plate chondrocytes infected with Ad-IGF1R or control adenovirus at an MOI of 50 and treated for
5dayswithorwithoutIGF-1(50ng/mL).(B)Immunoblottingofb-cateninfromwhole-celllysatesofgrowthplatechondrocytestreatedwithorwithoutAd-
IGF1R and IGF-1 for 5 days. Actin was used as an internal control. (C, D) Runx2 mRNA and cyclin D1 mRNA expression in growth plate chondrocytes treated
with Ad-IGF1R and/or IGF-1 for 5 days. (E) BrdU incorporation in growth plate chondrocytes treated with Ad-IGF1R and/or IGF-1 for 5 days. ( F) Col10a1
mRNA in growth plate chondrocytes treated with Ad-IGF1R and/or IGF-1 for 8 days. The data were expressed as the fold increase over the results of the
cells infected with control adenovirus.
 p<.05 versus control cells.
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active b-catenin (Fig. 4A), Runx2 mRNA, cyclin D1 mRNA, and
Col10a1 mRNA expression (Fig. 4B–D).
T3 promotes the PI3K/Akt signaling and PI3K/Akt-induced
b-catenin activation
To determine whether the effects of thyroid hormone also
were mediated by the IGF-1-dependent PI3K/Akt pathway, we
analyzed the activity of PI3K/Akt signaling by measuring the
phosphorylation of Akt and its downstream target GSK-3b.
Immunoblotting demonstrated increases in both pAkt and
pGSK-3b on day 4 of T3 treatment (Fig. 5A), in parallel with the
increase of Igf1r expression by T3 treatment (Fig. 1B). The level of
pGSK-3b also was increased on day 7 in conjunction with the
induction of active b-catenin (Fig. 5A).
In addition, we incubated T3-treated growth plate chondro-
cytes with the PI3K inhibitor LY294002 and the Akt inhibitor
Akti1/2. The addition of 20mM LY294002 or 1mM Akti1/2 led to
significant suppression of the T3-mediated increases in pGSK-3b
and active b-catenin in growth plate chondrocytes (Fig. 5B). Both
inhibitors also reversed the stimulatory effects of T3 on Wnt4,
Runx2, and cyclin D1 mRNA expression in the growth plate
chondrocytes (Fig. 5C–E).
T3-induced increases in Col10a1 mRNA expression and ALP
activity were inhibited when growth plate cells were treated
with T3 i nt h ep r e s e n c eo fL Y 2 9 4 0 0 2o rA k t i 1 / 2f o r5d a y s
(Fig. 5F,G).However,bothLY294002andAkti1/2hadnosignificant
effect on the hypertrophic markers when added to the cells
previously treated with T3 alone for 5 days (data not shown).
Discussion
These experiments performed in pellet culture systems show
that Igf1r expression is induced by thyroid hormone in
proliferating and prehypertrophic cells, the same population
of cells that express Igf1r in growth plate cartilage in vivo.
(12) Igf1
is expressed at much lower levels in growth plate chondrocytes
than in perichondrium and metaphyseal bone. IGF-1 protein in
the in vivo growth plate therefore is considered to derive
primarily from surrounding perichondrium and bone than from
the chondrocytes themselves.
(18) Thyroid hormone therefore
may regulate IGF-1 signaling in growth plate cells predominantly
at the receptor level, although T3 treatment also leads to a
transient increase in both Igf1 mRNA expression and IGF-1
protein release. The inhibition of T3 action by the IGF1R inhibitor
PPP supports a functional interaction between thyroid hormone
and IGF-1 signaling in the regulation of growth plate
chondrocyte growth and differentiation.
Our data demonstrate that IGF-1/IGF1R induces Wnt4
expression and b-catenin activation and also stimulates
growth plate chondrocyte proliferation and modestly promotes
Fig. 4. The effects of IGF-1/IGF1R on b-catenin signaling, cell proliferation, and terminal differentiation of growth plate chondrocytes are suppressed by
inhibition of Wnt signaling. (A) Immunoblotting of b-catenin from whole-cell lysates of growth plate chondrocytes treated with Ad-IGF1R (MOI of 50) and
IGF-1(50ng/mL)inthepresenceorabsenceofWntantagonistssFRP3(100ng/mL)andDkk1(100ng/mL)for5 days.(B,C)Quantitativereal-timeRT-PCRof
Runx2mRNA(B)andcyclinD1mRNAexpression(C)inratgrowthplatechondrocytestreatedwithAd-IGF1RandIGF-1for5daysinthepresenceorabsence
of sFRP3 and Dkk1. (D) Col10a1 mRNA expression in growth plate chondrocytes treated with Ad-IGF1R and IGF-1 for 8 days in the presence or absence of
sFRP3 and Dkk1.
 p<.05 versus the cells treated with Ad-IGF1R and IGF-1.
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on terminal differentiation are limited and not comparable in
magnitude with the effects of thyroid hormone treatment,
suggesting that the effects on hypertrophy consequently are
more likely to result from increasing the number of proliferating
cells recruited from resting cells. IGF-1/IGF1R actions on growth
platechondrocytesareneutralizedbythe Wntantagonists sFRP3
and Dkk1, confirming that the Wnt/b-catenin signaling pathway
is downstream of IGF-1 signaling.
The PI3K/Akt pathway has been reported to mediate
IGF-1-stimulated proliferation and differentiation in rat growth
plate chondrocytes and chondrogenic cell lines.
(22–24) The PI3K
pathway is also required for normal growth plate differentiation
and regulates endochondral bone growth.
(25) The delayed bone
Fig. 5. Thyroid hormone promotes IGF-1-activated PI3K/Akt signaling and PI3K/Akt-dependent b-catenin signaling in growth plate chondrocytes. (A)
Immunoblotting of phosphorylated Akt (pAkt), phosphorylated GSK-3b (pGSK-3b), and active b-catenin protein from whole-cell lysates of growth plate
chondrocytes treated with or without T3 (100ng/mL) for 2 to 7 days. Actin was used as an internal control. (B) Immunoblotting of pAkt, pGSK-3b, and b-
catenin protein of growth plate chondrocytes treated with T3 for 5 days in the presence or absence of PI3K signaling inhibitor LY294002 (20mM) and Akt
signaling inhibitor Akti1/2 (1mM). (C–E) Wnt4 mRNA(C), Runx2 mRNA (D), and cyclin D1 mRNA (E) expression of growth plate chondrocytes treated with T3
for 5 days in the presenceor absence of LY294002 and Akti1/2.
 p<.05 versus the cells treated with T3 alone. ( F, G) Col10a1 mRNA( F) and ALP activity (G)
of growth plate cells treated with T3 for 5 days in the presence or absence of LY294002 and Akti1/2.
 p<.05 versus the cells treated with T3 alone.
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similar to the phenotype of Igf1r knockout mice.
(26)
Our data show that T3 treatment stimulates PI3K/Akt/GSK-3b
signaling. The inhibition of PI3K/Akt activity by LY294002 and
Akti1/2 prevents T3-induced Wnt4 expression and b-catenin
activation. PI3K/Akt signaling may potentiate the activation of
Wnt pathways through the inactivation of GSK-3b and
stimulation of Wnt ligand expression. LY294002 and Akti1/2
also prevent T3-induced growth plate chondrocyte differentia-
tion but are unable to suppress terminal differentiation in cells
committed to hypertrophy. PI3K/Akt signaling therefore may
indirectly augment cell differentiation by promoting cell
proliferation and recruiting more cells undergoing hypertrophy.
These results indicate that IGF-1 is actively involved in
crosstalk between the Wnt/b-catenin and PI3K/Akt pathways in
the regulation of growth plate chondrocyte proliferation and
differentiation by thyroid hormone. Thyroid hormone receptors
(TRa) are predominantly expressed in resting zone (RZ) and
proliferating zone (PZ) growth plate chondrocytes,
(27) whereas
Igf1r is expressed in PZ and prehypertrophic zone (preHZ)
growth plate cells,
(12) and Wnt ligands are located primarily in
preHZ and hypertrophic zone (HZ) cells.
(28) We speculate that
thyroid hormone binds to its nuclear receptor in RZ and PZ cells
and initiates a series of events that lead the RZ cells to
differentiate into proliferating and hypertrophic cells. Thyroid
hormone initially may stimulate IGF-1/IGF1R signaling in PZ
growth plate chondrocytes, activating the b-catenin signaling
pathway through either the PI3K/Akt pathway or the Wnt
pathway, in turn regulating the transcription of b-catenin-
responsivegenes(eg,cyclinD1)andsubsequentlypromotingcell
proliferation in the growth plate.
Thyroid hormone–activated Wnt/b-catenin signaling is more
potentthan IGF-1signaling inpromotingterminal differentiation
of growth plate chondrocytes. IGF-1/IGF1R may indirectly
augment chondrocyte hypertrophy by potentiating cell pro-
liferation through the PI3K/Akt pathway, synergizing with the
Wnt signaling pathway in regulating the maturation of growth
plate chondrocytes.
The proposed interactions of these signaling pathways are
illustrated in Fig. 6. In conclusion, thyroid hormone promotes
growth plate cell differentiation and longitudinal bone growth
by activating b-catenin signaling via modulation of IGF-1/IGF1R
signaling through the Wnt and PI3K/Akt pathways. In addition
to the IGF-1/IGF1R, PI3K/Akt, and Wnt signaling pathways,
there are likely to be other pathways involved in the thyroid
hormone–mediated effects on growth plate chondocytes
because treatment with a combination of IGF1R inhibitors,
PI3K/Akti inhibitors, and Wnt antagonists has additive but not
complete inhibitory effects on the T3-induced terminal differ-
entiation (data not shown).
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